Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.81 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.81 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.81 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7271411 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DFEN1 | |
| SCHEMBL9077293 | 0.78 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DFEN1 | |
| SCHEMBL7280371 | 0.78 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DFEN1 | |
| SCHEMBL7273701 | 0.76 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DFEN1 | |
| SCHEMBL7279657 | 0.75 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DFEN1 | |
| SCHEMBL7340105 | 0.75 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL7328426 | 0.73 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL13143978 | 0.73 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL8803918 | 0.73 | PDE1A (0.56) | PDE4APDE4BPDE4CPDE4DFEN1 | |
| SCHEMBL7278277 | 0.73 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| EP-1613318-A4 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-04 | — | — | US | disclosed |
| EP-1613318-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087880-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PDE4A 106/4885PDE4B 122/4885PDE4C 95/4885 |
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | IAPP, SLC5A2, SLC5A1 | PDE4A 470/4885PDE4B 359/4885PDE4C 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.